![Study Results & Research Projects Study Results & Research Projects](https://webarchive.library.unt.edu/eot2008/20090201142822im_/http://ntp-server.niehs.nih.gov/images/template/subMastHead_studyResults.gif)
Summaries & Associations of Study Results
Summaries & Associations of Study Results
Home » Study Results & Research Projects » Summaries & Associations of Study Results » TR-508 Riddelliine
CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
---|---|---|---|---|
RIDDELLIINE 23246-96-0 |
10/18/01 | NATURALLY OCCURRING PHARMACEUTICAL AGENT | Gavage MR: 0 OR 1.0 MG/KG; 50/DOSE FR: 0, 0.01, 0.033, 0.1, 0.33, OR 1.0 MG/KG; 62/DOSE MM: 0, 0.1, 0.3, 1.0, OR 3.0 MG/KG; 50/DOSE FM: 0 OR 3.0 MG/KG; 50/DOSE | Southern Research Institute |
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
MR: CLEAR EVIDENCE | LIVER: HEMANGIOSARCOMA 0/50 43/50; ADENOMA 0/50 4/50 | |||
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS): 2/50 9/50 | ||||
NON-NEOPLASTIC LESIONS: | LIVER: REGENERATIVE HEPATOCYTE HYPERPLASIA; HEPATOCYTE CYTOMEGALY; FOCAL NECROSIS; EOSINOPHILIC FOCUS; MIXED CELL FOCUS; HEMORRHAGE | |||
KIDNEY: TUBULE NECROSIS | ||||
FR: CLEAR EVIDENCE | LIVER: HEMANGIOSARCOMA 0/50 0/50 0/50 0/50 3/50 38/50; ADENOMA 1/50 0/50 0/50 0/50 1/50 7/50 | |||
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS): 12/50 8/50 13/50 18/50 18/50 14/50 | ||||
NON-NEOPLASTIC LESIONS: | LIVER: REGENERATIVE HEPATOCYTE HYPERPLASIA; HEPATOCYTE CYTOMEGALY; FOCAL NECROSIS; EOSINOPHILIC FOCUS; MIXED CELL FOCUS; CLEAR CELL FOCUS; BILE DUCT HYPERPLASIA; HEMORRHAGE | |||
KIDNEY: TUBULE NECROSIS; TRANSITIONAL EPITHELIAL HYPERPLASIA | ||||
MM: CLEAR EVIDENCE | LIVER: HEMANGIOSARCOMA 2/50 1/50 0/50 2/50 31/50 | |||
OTHER :CONSIDERATIONS: | LIVER: ADENOMA 16/50 18/50 14/50 5/50 0/50 CARCINOMA 23/50 21/50 19/50 20/50 3/50 COMBINED 36/50 39/50 33/50 23/50 3/50 | |||
NON-NEOPLASTIC LESIONS: | LIVER: HEPATOCYTE CYTOMEGALY; HEPATOCYTE KARYOMEGALY; CENTRILOBULAR HEPATOCYTE NECROSIS; FOCAL HEMORRHAGE; INCREASED SEVERITY OF FOCAL HEPATOCYTE NECROSIS | |||
KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; GLOMERULOSCLEROSIS; TUBULE KARYOMEGALY; TUBULE DILATATION | ||||
FM: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/50 COMBINED 2/50 13/50 | |||
OTHER :CONSIDERATIONS: | LIVER: ADENOMA 9/59 0/50 OR CARCINOMA 8/49 0/50 COMBINED 16/49 0/50 | |||
NON-NEOPLASTIC LESIONS: | LIVER: HEPATOCYTE CYTOMEGALY; HEPATOCYTE KARYOMEGALY; CENTRILOBULAR HEPATOCYTE NECROSIS; FOCAL HEMORRHAGE; INCREASED SEVERITY OF FOCAL HEPATOCYTE NECROSIS | |||
KIDNEY: NEPHROPATHY; INCREASED SEVERITY OF NEPHROPATHY; GLOMERULOSCLEROSIS; TUBULE HYALINE DROPLET ACCUMULATION; TUBULE PIGMENTATION | ||||
LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA | ||||
ARTERIES (CHRONIC ARTERIAL INFLAMMATION INCLUDES FOCAL): SMALL INTESTINE (DUODENUM); LARGE INTESTINE (CECUM); KIDNEY; MESENTERY; OVARY; SPLEEN; UTERUS |
Web page last updated on February 10, 2006
The National Institute of Environmental Health Sciences is one of the National Institutes of Health within the U.S. Department of Health and Human Services. The National Toxicology Program is headquartered on the NIEHS campus in Research Triangle Park, NC.